SG11202111255YA - Methods for treating or preventing asthma by administering an il-33 antagonist - Google Patents

Methods for treating or preventing asthma by administering an il-33 antagonist

Info

Publication number
SG11202111255YA
SG11202111255YA SG11202111255YA SG11202111255YA SG11202111255YA SG 11202111255Y A SG11202111255Y A SG 11202111255YA SG 11202111255Y A SG11202111255Y A SG 11202111255YA SG 11202111255Y A SG11202111255Y A SG 11202111255YA SG 11202111255Y A SG11202111255Y A SG 11202111255YA
Authority
SG
Singapore
Prior art keywords
antagonist
administering
treating
methods
preventing asthma
Prior art date
Application number
SG11202111255YA
Inventor
Helene Goulaouic
Andreas Jessel
Raolat Abdulai
Ariel Teper
Alex Boddy
Chih-Chi Hu
Deborah Dukovic
Marcella Ruddy
Nikhil Amin
Sivan Harel
Georgios Kalliolias
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of SG11202111255YA publication Critical patent/SG11202111255YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202111255YA 2019-05-01 2020-04-30 Methods for treating or preventing asthma by administering an il-33 antagonist SG11202111255YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962841481P 2019-05-01 2019-05-01
US201962848248P 2019-05-15 2019-05-15
US201962898900P 2019-09-11 2019-09-11
PCT/US2020/030824 WO2020223541A1 (en) 2019-05-01 2020-04-30 Methods for treating or preventing asthma by administering an il-33 antagonist

Publications (1)

Publication Number Publication Date
SG11202111255YA true SG11202111255YA (en) 2021-11-29

Family

ID=70802932

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111255YA SG11202111255YA (en) 2019-05-01 2020-04-30 Methods for treating or preventing asthma by administering an il-33 antagonist

Country Status (15)

Country Link
US (1) US20210000949A1 (en)
EP (1) EP3962515A1 (en)
JP (1) JP2022530533A (en)
KR (1) KR20220004708A (en)
CN (1) CN113766931A (en)
AU (1) AU2020266593A1 (en)
BR (1) BR112021021195A2 (en)
CA (1) CA3138306A1 (en)
CO (1) CO2021015793A2 (en)
IL (1) IL287275A (en)
MA (1) MA55807A (en)
MX (1) MX2021013427A (en)
SG (1) SG11202111255YA (en)
TW (1) TW202106334A (en)
WO (1) WO2020223541A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092177A1 (en) 2012-08-21 2015-03-25 Sanofi Sa METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST
KR102462039B1 (en) 2016-09-01 2022-11-02 리제너론 파아마슈티컬스, 인크. A method for preventing or treating allergy by administering an IL-4R antagonist
WO2023025932A1 (en) 2021-08-27 2023-03-02 Medimmune Limited Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
WO2023086887A1 (en) * 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
WO2024042212A1 (en) 2022-08-26 2024-02-29 Medimmune Limited Treatment of asthma with an anti-interleukin-33 antibody

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
PT2374818E (en) 2006-06-02 2013-02-13 Regeneron Pharma High affinity antibodies to human il-6 receptor
PL2624865T3 (en) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
AR092177A1 (en) * 2012-08-21 2015-03-25 Sanofi Sa METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST
JO3532B1 (en) * 2013-03-13 2020-07-05 Regeneron Pharma Anti-il-33 antibodies and uses thereof
KR20220029765A (en) * 2014-02-21 2022-03-08 사노피 바이오테크놀로지 Methods for treating or preventing asthma by administering an il-4r antagonist
TW202332696A (en) * 2016-12-01 2023-08-16 美商再生元醫藥公司 Methods of treating inflammatory conditions
WO2018195472A1 (en) * 2017-04-21 2018-10-25 Genentech, Inc. Use of klk5 antagonists for treatment of a disease

Also Published As

Publication number Publication date
WO2020223541A1 (en) 2020-11-05
JP2022530533A (en) 2022-06-29
CO2021015793A2 (en) 2021-11-30
KR20220004708A (en) 2022-01-11
US20210000949A1 (en) 2021-01-07
TW202106334A (en) 2021-02-16
EP3962515A1 (en) 2022-03-09
BR112021021195A2 (en) 2022-03-03
CA3138306A1 (en) 2020-11-05
CN113766931A (en) 2021-12-07
IL287275A (en) 2021-12-01
MX2021013427A (en) 2022-01-31
AU2020266593A1 (en) 2021-11-11
MA55807A (en) 2022-03-09

Similar Documents

Publication Publication Date Title
IL274134A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
IL287275A (en) Methods for treating or preventing asthma by administering an il-33 antagonist
PT3107575T (en) Methods for treating or preventing asthma by administering an il-4r antagonist
IL285496A (en) Methods for treating cholestasis
IL282600A (en) Composition and method for treating the lungs
IL289930A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
IL290833A (en) Compositions and methods for cll1 modification
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
IL285886A (en) Compositions and methods for treating laminopathies
IL287907A (en) Methods for treating cancer
IL285847A (en) Methods for treating map3k8 positive cancers
GB201903827D0 (en) New compounds and methods
IL290770A (en) Compounds and methods for treating oxalate-related diseases
IL286653A (en) Methods for treating muscular dystrophy with casimersen
IL289731A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
IL294066A (en) Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
SG11202010911WA (en) Methods and compositions for treating chronic urticaria
IL288953A (en) Pharmaceutical compositions, kits and methods for treating tumors
IL285796A (en) Methods and compositions for treating
EP4027874C0 (en) Method for determining respiratory rate
IL293544A (en) Methods for treating copd by administering an il-33 antagonist
EP3941921A4 (en) Therapeutic methods for treating hepatitis b
EP3958858A4 (en) Methods for treating against viruses
GB201906201D0 (en) Method for the detection of protate cancer
EP3891179A4 (en) Methods and compositions for treating asthma